top of page
Image by Hal Gatewood

Transformative Breast Cancer Consortium
The Immune Solution to End Breast Cancer

The Transformative Breast Cancer Consortium (TBCC) consists of an integrated team of investigators. Our project groups were selected due to their extensive scientific interest and expertise, communication and collaborative research skills, and a shared perspective of their research goals

Pipetting Samples
Upcoming Events and Deadlines
​​November 2024 (no monthly TBCC meeting due to holiday)
  • 11/11:  ZOOM Meeting: Salon Hours (2 pm EST)
  • 11/21:  ZOOM Prep for IPR Meeting (3 pm EST)​​​​
 
December 2024 (no monthly TBCC meeting due to holiday)
  • 12/5:  ANNUAL DOD IPR Meeting 1:25pm EST (In Person)​​
  • 12/9:  ZOOM Meeting: Salon Hours (2 pm EST)​​
 
January 2025
  • 1/13:  ZOOM Meeting: Salon Hours (2 pm EST)
  • 1/23: ZOOM Meeting: TBCC BiAnnual Workshop (3 pm EST)
image-asset.png

Project 1

Profiling the human breast tumor ecosystem to identify regulators of anti-tumor immunity

image.png

Patient Advocate Michele Atlan

Project 2

Dissecting the mechanisms of immune evasion employed by cancer drivers in breast cancer

Patient Advocate Michele Rakoff

image.png
homedna.png
Hospital Staff

Project 3

Targeting the epigenome as a therapeutic strategy for breast cancer

image.png

Patient Advocate Vernal Branch

Project 4

Study of the mammary myeloid regulation of T cells as a critical innate-adaptive immune checkpoint axis in the progression of BC

Patient Advocate Patty Spears

image.png
Crainbow 2.webp
Microscope

Project 5

A live biobank at inflexion points of triple negative breast cancer: the DIGNITY study

Concrete Wall

TBCC Funded
Seed Projects

Generation of a novel octo-genic immune tolerant mouse (Octo-NG) to better model syngeneic tumor studies in fully immune-competent mice for TBCC groups

Zachary Hartman, PhD and Timothy Trotter, PhD

Duke University

Discovery of a dual combination WNT and PD-1/PD-L1 blockade therapy for treatment resistant and metastatic HER2+ breast cancers.

Joshua C. Snyder, Ph.D., Chaitanya R. Acharya, Ph.D., Joshua D. Ginzel, & Alexander Borowsky, M.D.

Duke University and UC Davis

Creating a 3D TNBC model of PTEN deficiency to discover immunoregulatory tumor epitopes

Wen Shen, PhD

Weill Cornell Medical College

Investigation of IGHG4/IgG4 expression in Breast Cancer

Co-Teams: Simon Knott, PhD and  Zachary Hartman, PhD  

Cedars-Sinai and Duke University

Identifying microenvironmental determinants of reduced immune checkpoint blockade efficacy in bone

Timothy Trotter, PhD and  Erika Crosby, PhD  

Duke University

Exploring the IL33/ST2 Axis as a Target in Breast Cancer Therapy

Natalie Thomas and  Amy Hobeika, PhD  

Duke University

Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent "NoGlow" Mice

Trotter TN, Wilson A, McBane J, Dagotto CE, Yang XY, Wei JP, Lei G, Thrash H, Snyder JC, Lyerly HK, Hartman ZC. Cancer Res Commun. 2024 Apr 9;4(4):1050-1062.

Dormant tumors circumvent tumor-specific adaptive immunity by establishing a Treg-dominated niche via DKK3

Trotter TN, Dagotto CE, Serra D, Wang T, Yang X, Acharya CR, Wei J, Lei G, Lyerly HK, Hartman ZC. JCI Insight. 2023 Nov 22;8(22):e174458

Empowering anti-cancer immunity: CD27 activation drives memory CD4+ antigen specific T cell memory responses and is essential for anti-tumor immunity

Hwang BJ, Crosby E, Trotter T, Tsao LC, Wang T, Liu CX, Yang X, Lei G, Wei J, Ma X, Liu B, Hobeika A, Morse M, Kanu E, Agritelley E, Keler T, He LZ, Lyerly HK, Hartman ZC.  Science Immunology (in revision)

AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution

Schade, A.E., Perurena, N., Yang, Y. et al. Nature (2024). 

Publications
 

Get in Touch

203 Reseach Drive, Suite 433

Durham, NC 27710

919-681-8350

  • Facebook
  • Twitter
  • LinkedIn
  • Instagram

Thanks for submitting!

bottom of page